文献速递其他结缔组织病

皮肤肌炎恶性肿瘤筛查:PET费用低于传统筛查组合

Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis.
PubMed 文献 · Semin Arthritis Rheum · 2018-11-02

该研究基于2005-2014年美国商业保险索赔数据,比较PET及PET-CT四种方案与传统恶性肿瘤筛查组合的费用。结果显示全身PET-CT对保险公司的总费用高于传统组合(男性高730.70美元、女性高537.62美元),但患者自付费用更低(男性低109.82美元、女性低111.33美元)。PET-CT可能对监测间质性肺病进展有附加价值。

要点

  • 全身PET-CT对保险公司总费用高于传统筛查组合,但患者自付费用更低。
  • PET-CT可能对监测皮肤肌炎患者间质性肺病进展有附加价值。
  • PET-CT检测皮肤肌炎相关恶性肿瘤的效力尚需更多数据,费用差异小于预期。

核心结论

  • 全身PET-CT对保险公司的总费用高于传统筛查组合,但患者自付费用低于传统组合。
  • PET-CT可能对检测和监测皮肤肌炎患者间质性肺病进展有附加价值。
  • PET-CT检测皮肤肌炎相关恶性肿瘤的效力尚需更多数据,但费用差异小于预期,单次扫描对部分患者可能是合理替代方案。

研究设计与样本

  • 研究纳入四种PET及PET-CT变体,传统筛查组合包括腹部盆腔平扫CT、胸部平扫CT、CEA、CA19.9、PSA(男性)、乳腺钼靶(女性)、经阴道超声(女性)、细胞病理学(女性)和CA125(女性)。
  • 比较PET变体与传统组合对保险公司的平均总费用及患者平均自付费用,并评估同期肺功能检查(PFT)费用。

主要发现

  • 2005至2014年,PET平均通胀调整后费用呈下降趋势,而PET-CT平均费用呈上升趋势。
  • 全身PET-CT对保险公司的平均总费用比传统组合男性高730.70美元、女性高537.62美元。
  • 全身PET-CT患者自付费用比传统组合男性低109.82美元、女性低111.33美元。
  • PFT平均总费用为205.02美元。

关键数值与推荐

  • 全身PET-CT对保险公司平均总费用比传统组合男性高730.70美元、女性高537.62美元。
  • 全身PET-CT患者自付费用比传统组合男性低109.82美元、女性低111.33美元。
  • PFT平均总费用为205.02美元。

临床怎么用

  • 对于皮肤肌炎患者,全身PET-CT虽增加保险公司总费用,但可降低患者自付费用。
  • PET-CT可能作为单次扫描替代传统恶性肿瘤筛查组合,尤其适用于部分患者,并可能监测间质性肺病进展。

局限性

  • PET-CT检测皮肤肌炎相关恶性肿瘤的效力尚需更多数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dermatomyositis (DM) is associated with malignancy and interstitial lung disease. Many malignancies associated with DM occur in organs not routinely screened by national guidelines; thus, best screening practices are still debated. Positron emission tomography (PET) has been suggested as a single study alternative to more complex screening panels and may also be valuable in detecting interstitial lung disease progression. Criticisms of PET screening exams have focused on cost and radiation exposure. OBJECTIVE: To compare the cost of PET and its variants to conventional malignancy screening panels, and to review concerns regarding radiation exposure in PET. METHODS: Four variants of PET and PET-CT were included in the study. The conventional screening panel was defined as CT of the abdomen and pelvis without contrast, CT of the thorax without contrast, CEA, CA 19.9, PSA (men), mammography (women), transvaginal ultrasound (women), cytopathology (women), and CA 125 (women). The MarketScan® Commercial Claims and Encounters database, a collection of private insurance claims data from 53 million Americans, was queried for every instance of each test from 2005 to 2014 and the mean inflation-adjusted cost of each was recorded. The mean total cost to insurance companies and the mean out-of-pocket costs to patients for PET variants were compared to the costs for conventional panels. Additionally, the cost of pulmonary function tests (PFT) from the same period was evaluated. RESULTS: From 2005-2014, the mean inflation-adjusted costs of PET have trended downward, but the mean cost of PET-CT have trended upward. The mean total cost to insurance companies for PET-CT whole body was $730.70 and $537.62 greater than the cost of conventional panels for men and women, respectively. The out-of-pocket patient costs for PET-CT whole body was $109.82 and $111.33 less than the cost of conventional panels for men and women, respectively. The mean total cost of PFT was $205.02. CONCLUSIONS: The cost of PET-CT whole body was greater than conventional panels for insurance companies, but patient out-of-pocket costs were lower. PET-CT may also have added value in detecting and monitoring interstitial lung disease progression in DM patients. More data are needed on the efficacy of PET-CT in detecting malignancy in DM patients; however, the cost difference is less than expected, suggesting the single scan could be a reasonable alternative to the conventional screening panel in some patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kundrick A, Kirby J, Ba D, et al. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum. 2018. PMID: 30482435. doi:10.1016/j.semarthrit.2018.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。